Direct-to-Consumer Surgery: Non-invasive liposuction for the masses

Not so very long ago, reimbursement was king in the world of medical devices. But the overnight success of injectible anti-wrinkle drug Botox signalled a change in the market. Now device companies developing liposuction alternatives hope to repeat that success, perhaps most importantly, in building their businesses outside of traditional reimbursement circles with a largely consumer-driven or self-pay market with new devices for cosmetic surgery applications.

Not so very long ago, reimbursement was king in the world of medical devices. Without reimbursement, there was no market, particularly for devices that had any degree of invasiveness to them. For that reason, if companies with surgical or even minimally invasive devices dreamed of one day selling to the virtually unlimited consumer market, they took the high road to the marketplace, by targeting a dire, and reimbursable, medical need first. Thus, Allergan Inc. , which had a multi-focal lens that could help the middle aged see both near and far without reading glasses, positioned its implantable device for the cataract market. Medtronic Inc. , looking into the market for obesity devices, got its electrical stimulation device approved for gastroparesis, an uncommon but horrendous disorder that causes frequent vomiting. (See "Obesity: Supersized Medical Device Market Also see "Obesity: Super-Sized Medical Device Market " - Medtech Insight, 1 March, 2003.) And injectable anti-wrinkle drug Botox (botulinum toxin) first entered the market as a therapy for a rare facial twitching disorder. But things are changing, and it was perhaps the overnight success of Botox that first signaled this shift.

Botox has boomed since its introduction in 2000; there were 1.6 million Botox injections in 2002, up 4% over the...

More from Policy & Regulation

Dermal Fillers For Décolletage May Gain FDA Approval

 
• By 

An upcoming US FDA advisory panel meeting will discuss adding a new indication to allow dermal fillers to be used in the upper chest, or décolletage. Plastic surgeons expect this could drive interest in the procedure, which is already performed off-label.

South Korean Health Ministry Sees Benefits Of Pre-Regulatory Review

 
• By 

A system of pre-regulatory review consultations for innovative drugs and devices in South Korea has contributed to the accelerated development of such products.

Court Orders US FDA To Return Trial Diversity Action Plan Guidance To Website

 
• By 

HHS and its agencies violated the law by swiftly implementing “sweeping and poorly thought-through directives that ordered the bulk removal of healthcare resources,” including FDA draft guidances on diversity action plans and sex differences in clinical trials, a federal court said.

Planning To Take Part in MDUFA? FDA Wants To Hear From You

 

The US FDA needs to know who wants a seat at the MDUFA negotiations table before discussions can begin. The agency is asking stakeholders to let it know if they plan to participate in the periodic consultation meetings before July 28.

More from Medtech Insight

Court Orders US FDA To Return Trial Diversity Action Plan Guidance To Website

 
• By 

HHS and its agencies violated the law by swiftly implementing “sweeping and poorly thought-through directives that ordered the bulk removal of healthcare resources,” including FDA draft guidances on diversity action plans and sex differences in clinical trials, a federal court said.

Planning To Take Part in MDUFA? FDA Wants To Hear From You

 

The US FDA needs to know who wants a seat at the MDUFA negotiations table before discussions can begin. The agency is asking stakeholders to let it know if they plan to participate in the periodic consultation meetings before July 28.

Global Medtech Guidance Tracker: June 2025

 
• By 

Stay current on regulatory guidelines from around the world with Medtech Insight's Guidance Tracker. Over 50 documents have been posted on the tracker since its last update.